ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Quinidine

Also written as “AVP-786”, “Quinidine Sulfate” and “Quinidine sulfate tablets”.

Its studies are mostly in Psychomotor Agitation · Schizophrenia · Dementia · Disruptive, Impulse Control, and Conduct Disorders, led by 4 companies.

Drug pageQuinidine: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 11, 201517 company-led studies, 1 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka130 open or runningphase 3since May 11, 2015Jun 23, 2014none ahead
Boehringer Ingelheimits history only20 open or runningphase 1since Jun 20, 2014Jun 20, 2014none ahead
Bristol-Myers Squibbits history only10 open or runningphase 1since Jun 25, 2024Jun 25, 2024none ahead
Trevi Therapeuticsits history only11 open or runningphase 1since Nov 12, 2026Nov 12, 2026Nov 30, 2026phase 1 · NCT07946575

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 23, 2014First studies: 2 phase 1 studiesFirst studyNCT02174835, NCT02174822
  2. Jan 8, 2015Phase 1 study in Healthy VolunteerNCT02336347 · 62 enrolled · United States
  3. Feb 26, 2015Phase 1 study in HealthyNCT02402595 · 24 enrolled · United States
  4. May 11, 20152 phase 3 studiesNCT02446132, NCT02442765
  5. Jun 18, 2015Phase 2 study in SchizophreniaNCT02477670 · 145 enrolled · United States
  6. Aug 11, 2015Phase 2 study in Disinhibition SyndromeNCT02534038 · 1 enrolled · United States
  7. Jan 3, 2018Phase 3 study in Psychomotor AgitationNCT03393520 · 601 enrolled · United States, Australia, Bulgaria and more
  8. Jan 19, 2018Phase 2 study in Disruptive, Impulse Control, and Conduct DisordersNCT03420222 · 10 enrolled · United States
  9. Mar 19, 2019Phase 3 study in SchizophreniaNCT03896945 · 136 enrolled · United States, Bulgaria, Poland and more
  10. May 26, 2020Phase 3 study in Psychomotor AgitationNCT04408755 · 184 enrolled · United States, Bulgaria, Denmark and more
  11. Jul 6, 2020Phase 3 study in Psychomotor AgitationNCT04464564 · 241 enrolled · United States, Belgium, Canada and more

TargetBeta

“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 13 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04464564Psychomotor Agitation · United States, Belgium, Canada and more3TerminatedJun 28, 2024241
NCT04408755Psychomotor Agitation · United States, Bulgaria, Denmark and more3TerminatedJun 27, 2024184
NCT03896945Schizophrenia · United States, Bulgaria, Poland and more3TerminatedMay 23, 2023136
NCT03420222Disruptive, Impulse Control, and Conduct Disorders · United States2TerminatedDec 28, 201810
NCT03393520Psychomotor Agitation · United States, Australia, Bulgaria and more3CompletedNov 17, 2023601
NCT02534038Disinhibition Syndrome · United States2TerminatedOct 3, 20171
NCT02477670Schizophrenia · United States2CompletedJul 21, 2017145
NCT02446132Agitation in Patients With Dementia of the Alzheimer's Type · United States, Bulgaria, Canada and more3TerminatedSep 6, 20241,197
NCT02442765Psychomotor Agitation · United States, Estonia, Germany and more3CompletedJan 30, 2019387
NCT02402595Healthy · United States1CompletedJul 1, 201524
NCT02336347Healthy Volunteer · United States1CompletedSep 1, 201462
NCT02174835Healthy · Australia1CompletedNov 1, 201356
NCT02174822Drug-drug Interaction · Australia1CompletedMar 201456

How it is read

Names in the registry

  • “AVP-786”, 13 entries
  • “Quinidine Sulfate”, 1 entry
  • “Quinidine”, 1 entry
  • “Quinidine sulfate tablets”, 1 entry
  • “quinidine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.